SPRO - Spero Therapeutics, Inc.
| Previous Close | 12.31 |
| Open | 12.29 |
| Bid | 9.55 x 800 |
| Ask | 32.50 x 1300 |
| Day's Range | 11.76 - 12.30 |
| 52 Week Range | 5.52 - 14.48 |
| Volume | 46,313 |
| Avg. Volume | 56,075 |
| Market Cap | 223.315M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.83 |
- Zacks
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update
CAMBRIDGE, Mass., Aug. 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Zacks
Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it has received a $5.9 million award from the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (Award number W81XWH-19-1-0295). The U.S. Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD 21702- 5014 is the awarding and administering acquisition office. The funding will support the further clinical development of SPR206, Spero’s intravenous (IV)-administered product candidate from its Potentiator Platform that is being developed as an innovative alternative option to treat MDR Gram-negative bacterial infections.
- Simply Wall St.
Did Changing Sentiment Drive Spero Therapeutics's (NASDAQ:SPRO) Share Price Down By 15%?
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...
- GlobeNewswire
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 28, 2019 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- GlobeNewswire
Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute (Gates MRI) to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb), an indication that is designated as a critical concern by the World Health Organization (WHO). SPR720 is an orally administered antimicrobial agent currently being developed by Spero Therapeutics for the treatment of rare non-tuberculous mycobacterial (NTM) infections. Spero has granted Gates MRI an exclusive license to develop, manufacture and commercialize SPR720 for the treatment of tuberculosis (TB) in low- and middle- income countries (LMIC). Gates MRI will conduct and fund preclinical and clinical studies for the development of SPR720 against TB, and also fund certain collaborative activities in furtherance of Gates MRI’s charitable purposes. SPR720 was discovered by Vertex Pharmaceuticals and was acquired by Spero Therapeutics in 2016.
- GlobeNewswire
Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
CAMBRIDGE, Mass., June 17, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- GlobeNewswire
Spero Announces $10 Million Registered Direct Offering of Common Stock
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it has entered into a definitive agreement to sell up to $10,000,000 of Spero’s common stock in a registered direct offering with Novo Holdings A/S to be issued in two tranches. The first tranche of the offering consists of 465,983 shares sold at a price of $10.73 per share, for aggregate gross proceeds to the Company of approximately $5,000,000, and is expected to close on or about June 14, 2019, subject to the satisfaction of customary closing conditions. The closing of the second tranche of $5,000,000 is triggered upon the earlier of (i) Spero’s public announcement of pharmacokinetic data from the lead-in cohort in its Phase 3 clinical trial of SPR994 and (ii) June 30, 2020. The number of shares to be sold in the second tranche will be determined by the volume weighted average trading price (VWAP) of Spero’s common stock around the trigger date.
- Zacks
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 62.34% and 517.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
CAMBRIDGE, Mass., May 09, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Zacks
Analysts Estimate Spero Therapeutics, Inc. (SPRO) to Report a Decline in Earnings: What to Look Out for
Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Skift
Marriott Is Officially Getting Into the Homesharing Business
Marriott, the world's largest hotel company with more than 7,000 hotels around the world, is officially getting into the homesharing business with the launch of Homes & Villas by Marriott International in 100 destinations. A year after it began conducting a homesharing pilot, the 91-year-old hotel group appears convinced it can compete with travel disruptors […]The post Marriott Is Officially Getting Into the Homesharing Business appeared first on Skift.
- GlobeNewswire
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- Zacks
Spero Gets Fast Track Designation for SPR994, Shares Improve
Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
- GlobeNewswire
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
CAMBRIDGE, Mass., March 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.
- GlobeNewswire
Spero Announces Appointment of Cynthia Smith to its Board of Directors
Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced the appointment of Cynthia Smith to its Board of Directors, effective as of today. “We are pleased to welcome Cynthia to our Board of Directors,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.
- Zacks
Will Spero Therapeutics Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Spero Therapeutics.
- Business Wire
Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review
Anticipated 2019 Events include Enrollment in the Planned SPR994 Pivotal Phase 3 Clinical Trial and Top-Line Data from SPR720 and SPR206 Phase 1 Clinical Trials in 2H19
- Associated Press
Airbnb, HomeAway lose legal challenge to Santa Monica rules
Short-term rental sites Airbnb and HomeAway lost a legal challenge Wednesday against an ordinance enacted by a popular California tourist city. The ordinance imposed several obligations involving rental sites in seaside Santa Monica, including refraining from booking properties that are not licensed and listed on a city registry. A 9th U.S. Circuit Court of Appeals panel ruled that a lower court properly dismissed the legal challenge over its failure to state a claim against the city.
- Bloomberg
Airbnb Loses Major Fight Over California City's Rental Law
The ruling Wednesday by a three-judge panel of the Ninth Circuit is a setback for the home-sharing platforms in their effort to avoid regulation by cities that blame the rapid proliferation of short-term rentals for a shortage of affordable housing and a disintegration of residential communities. The Santa Monica ordinance holds the companies responsible for booking rentals of residences that aren’t licensed by the city. San Francisco-based Airbnb is the largest home-rental platform with more than 6 million listings around the world.
- GlobeNewswire
Spero Therapeutics to Present at March Investor Conferences
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero’s lead product candidate, SPR994, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero has begun start-up activities for the ADAPT-PO Phase 3 clinical trial of SPR994 for the treatment of complicated urinary tract infections and anticipates opening trial sites to support study enrollment in the first quarter of 2019. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of non-tuberculous mycobacterial (NTM) infections. In January 2019, Spero initiated a Phase 1 clinical trial of SPR720 in healthy subjects and expects top-line data from this trial in the second half of 2019.
